Premier Research announced the appointment of John Ratliff to the position of Chief Executive Officer and Board member. In this position, he succeeds Ludo Reynders, Ph.D., who will be retiring and will become an advisor to the company and remain a board member.
During his 13 years with the company, Dr. Reynders led the successful development of the company as a leading provider of clinical development services to product innovators primarily in the Biotechnology sector.
Mr. Ratliff brings a wealth of sector experience and achievement to the company, including most recently as CEO and Chairman of Curia, a contract research and development organization. Prior to Curia, Mr. Ratliff was CEO of Covance, the drug development business within LabCorp. Mr. Ratliff also served in various roles at Quintiles (now IQVIA), a leading contract research organization, including CFO, COO, President, and board member.
"I am pleased to welcome John to Premier – a leading provider of development services to innovators in the pharmaceutical industry. I have the greatest confidence that under his leadership the company will continue to thrive and be a formidable home for our customers, employees, and investors," said Dr. Reynders.
Incoming CEO Mr. Ratliff commented that, "This is a unique opportunity to build on the strong organizational foundations laid by Ludo. I look forward to realizing the full potential of the organization. The combination of our clinical expertise, customer and patient centricity, and fit for purpose technology provides an unmatched opportunity to achieve what we've set out to be: a service company that is built for innovation."
Write comment (0 Comments)
SGD Pharma, global primary glass packaging leader, has announced the appointment of Fabio Invernizzi as its new General Manager of its West BU. The BU West includes SGD Pharma’s commercial activities for MEA, North and South America and our manufacturing footprint in Europe. Fabio joins the Group Executive Committee bringing over 15 years of experience in Commercial, Marketing and Business Development at a senior level for the life science industry. He joins SGD Pharma following his last position as Vice-President and EMEA BU Head of Capsules and Health Ingredients at Lonza. Prior to that role, Fabio led the Global Commercial & Business Development activities for the Capsules & Heath Ingredients Division at Lonza.
Commenting on his appointment, Fabio said: “In starting this next chapter, I am excited to join the experienced SGD Pharma team working alongside CEO Olivier Rousseau and the Executive Committee. I am eager to continue writing the success story of SGD Pharma with my team and colleagues - I believe we can bring the company to the next level of leadership in Europe in the Primary Pharmaceutical Packaging market. Together with the strong team in place, I also look forward to continuing to grow in the Americas.”
Fabio picks up the baton of West BU General Manager from Laurent Zuber, who will retire in January 2024 after a long lasting and successful career at Saint-Gobain and SGD Pharma. SGD Pharma would like to thank Laurent Zuber who led the commercial activities of the group and the General Management of the West BU with passion and dedication. The company also shares its deep gratitude to Laurent for building the customer relationships it has today and for expanding its product portfolio in molded and tubular.
Write comment (0 Comments)